# EDGAR Filing Document

**Accession Number:** 0001807983
**File Stem:** 0001171843-23-001133
**Filing Date:** 2023-2
**Character Count:** 2590
**Document Hash:** 04f8b0c5f6e192d4b6db46dd82b29645
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-001133.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001171843-23-001133

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medicenna Therapeutics Corp.
- **CENTRAL INDEX KEY:** 0001807983
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2 BLOOR ST W., 7TH FLOOR
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4W 3E2
- **BUSINESS PHONE:** 416 648-5555

**MAIL ADDRESS:**
- **STREET 1:** 2 BLOOR ST W., 7TH FLOOR
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M4W 3E2

**MEDICENNA THERAPEUTICS CORP.**

**2 Bloor St. W., 7th Floor**

**Toronto, Ontario M4W 3E2**

**Canada**

February 23, 2023

**VIA EDGAR** 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Daniel Crawford

---

| | |
|:---|:---|
| **RE:** | **Medicenna Therapeutics Corp.** |
|  | **Registration Statement on Form F-3** |
|  | **Filed February 17, 2023** |
|  | **File No. 333- 269868** |
|  | **<u>Acceleration Request</u>** |

---

Dear Mr. Crawford:

With respect to the above-referenced Registration Statement on Form F-3 (the "Registration Statement"), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Medicenna Therapeutics Corp. (the "Company"), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to February 27, 2023, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call John Rudy and Keunjung Cho of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.

---

| |
|:---|
| Very truly yours, |
| MEDICENNA THERAPEUTICS CORP. |
| <u>/s/ Elizabeth Williams</u> |
| Elizabeth Williams |
| Chief Financial Officer |

---

---

| | |
|:---|:---|
| **cc:** | Elizabeth Williams, *Medicenna Therapeutics Corp.* |
|  | John Rudy, Esq., *Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.* |
|  | Keunjung Cho, Esq., *Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.* |

---